Chinese patent expiration dates draw closer for Novo Nordisk
In coming years, Novo Nordisk will take blows in the shape of several patents terminating on the second-biggest market for the firm, a Danish media reports.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
After a string of years characterized by growth for Novo Nordisk, in 2022, the Danish pharmaceutical firm has been hit by a large pricing reform in China. More challenges loom on the horizon in the country, which is the firm’s second-biggest market, as reported by Danish media Finans.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk remains coy over Wegovy blockbuster potential
For subscribers
.jpg)
.jpg&w=384&q=75)
